2021
2021
IsoPlexis has received the highly coveted Red Dot Award: Product Design 2021. The international jury has awarded the IsoSpark the "Red Dot" distinction for high design quality. Additionally, the IsoSpark received a second award as an "Innovative Product" in recognition of its novel and highly innovative features. "We are excited that our IsoSpark system received the Red Dot Award, as we continue to expand access to the unique insights at the convergence of single-cell biology and proteomics with our revolutionary benchtop system," said Sean Mackay, IsoPlexis' Co-Founder and CEO. "We strive to help accelerate key critical areas of life sciences research and the advancement of personalized, curative medicines." The IsoSpark can be seen in the online exhibition on the Red Dot website from June 21, 2021. That date also marks the beginning of the Red Dot Design Week, during which this year's award winners and IsoPlexis will be celebrated online.
2021
IsoPlexis today announced that it has been named by Fierce Medtech as one of 2020's Fierce 15, designating it as one of the most promising private companies in the industry. "We are honored to be recognized as a Fierce 15 company by Fierce Medtech," said CEO and Co-Founder of IsoPlexis, Sean Mackay. "We are on a mission to leverage our powerful single cell proteomic biology to accelerate a wide array advanced, curative medicines. Our team and user base have grown significantly over the past year, and we are looking forward to drive more exciting breakthroughs as we scale." The Fierce 15 celebrates the spirit of being "fierce" — championing innovation and creativity, even in the face of intense competition. "Each member of this year's class of Fierce 15 stands out in a different way, but they all overcame a year of unforgettable obstacles, making each of their successes that much more significant — and all have the potential to deliver changes in healthcare that promise to outlast this pandemic," said Conor Hale, associate editor of Fierce Medtech.
2021
IsoPlexis today announced that its IsoSpark system has been named a winner in the 2021 BIG Innovation Awards presented by the Business Intelligence Group. The breakthrough IsoSpark platform is a critical tool that provides new and accessible layers of biological data at the single-cell level, and the ability to interrogate the secreted proteome, the phosphoproteome, and the metabolome from single cells for the first time. This allows researchers to connect more deeply to in vivo biology, and predict complex responses to therapies and disease in cancer immunotherapy, cell and gene therapy, COVID-19, autoimmune disease, and many other areas. "More than ever, the global society relies on innovation to help progress humanity and make our lives more productive, healthy and comfortable," said Maria Jimenez, Chief Operating Officer of the Business Intelligence Group. "We are thrilled to be honoring IsoPlexis as they are one of the organizations leading this charge and helping humanity progress."
2021
IsoPlexis, the leader in single-cell functional proteomics, today announced a $135 million Series D financing to accelerate global expansion of installed base and deliver new solutions at the convergence of single-cell biology and proteomics. The round was led by Perceptive Advisors with participation from other new investors, Ally Bridge Group and funds and accounts managed by BlackRock, as well as other existing investors. IsoPlexis will use the proceeds from this financing to expand its global commercial and R&D teams, increase operational capacity to satisfy growing demand, and accelerate its next generation single-cell biology product development roadmap. "We are grateful to our new and existing investors for their support of our vision," said Sean Mackay, Chief Executive Officer and Co-founder of IsoPlexis. "With more than 100 systems placed and a strong team of over 200 employees, we have laid an incredibly strong foundation for future growth at the convergence of single-cell biology, proteomics, and multi-omics. We look forward to deploying this capital to accelerate our commercial efforts as we work to leverage our powerful biology to impact the future of advanced medicines."
2020
2020
IsoPlexis, the leader in single-cell functional proteomics, announced today that Chief Executive Officer and Co-Founder, Sean Mackay, will present at Citi's Spotlight on Diagnostics on Thursday, December 17th. The fireside chat, The Impact of Single-Cell Proteomics on Precision Medicine, will take place at 12:00 PM ET.
2020
IsoPlexis' Single-Cell Intracellular Proteome solution has been recognized for its impact on the development of better targeted and edited therapies and its potential to innovate and accelerate medical research. The Single-Cell Intracellular Proteome chip provides a simple, integrated solution for monitoring simultaneous protein signaling networks that are missed by methods such as western blot, mass spectrometry, and flow cytometry. This solution can be used on all of IsoPlexis' benchtop proteomics systems, including the IsoSpark, IsoLight, and IsoSpark Duo. Single-Cell Intracellular Proteome uses IsoPlexis' proprietary proteomic barcoding to characterize phosphoprotein signaling cascades targeting up to 1500 single cells per chip. The first available panel monitors multiple highly multiplexed protein pathways at the single-cell level, with more panels to come in 2021. "IsoPlexis is honored to have the Single-Cell Intracellular Proteome solution recognized by The Scientist as a Top Innovation of 2020," said Sean Mackay, IsoPlexis Chief Executive Officer and Co-Founder. "By understanding the entire network of cellular signaling pathways, IsoPlexis reveals the effects of aberrant pathways typically missed in rare subsets of cells, which can help researchers develop more comprehensive treatments for cancer, faster."
2020
IsoPlexis, the leader in single-cell functional proteomics, announced today that Chief Executive Officer and Co-Founder, Sean Mackay, will present at Evercore ISI's 3rd Annual HealthCONx Conference on Wednesday, December 2nd at 9:40 a.m. ET.
A live webcast of the fireside chat will be made available on the company's website at isoplexis.com.
2020
IsoPlexis, the leader in single-cell functional proteomics, announced today that biomarker and translational data from the PIVOT-02 study using IsoPlexis' functional proteomics platform was presented at the 2020 SITC conference. The presented data from the clinical trial examines T cell response to Nivolumab (Nivo) immunotherapy in combination with Nektar's bempegaldeskleukin (NKTR-214, BEMPEG) IL-2 pathway agonist.
IsoPlexis' technology identified a non-invasive, blood-based biomarker predicted response to the doublet. IsoPlexis began its collaboration with Nektar Therapeutics in June of 2018. IsoPlexis' functional immune landscaping has been used to profile the effects of BEMPEG in both monotherapy and combination immunotherapies in a clinical setting. "We are excited to demonstrate that predictive blood-based biomarkers in cancer immunology are possible by harnessing powerful T-cell responses using IsoPlexis' single-cell functional proteomics," said IsoPlexis' CEO, Sean Mackay.
2020
IsoPlexis today announced the launch of their groundbreaking new systems for functional proteomics. With this launch, IsoPlexis adds the IsoSpark and IsoSpark Duo to their product suite. These technologies provide the same end-to-end automation and highly multiplexed proteomics capabilities as the IsoLight system with increased scalability, providing a system for every lab's needs.
The IsoSpark has a reduced 18-inch footprint and a 4-chip capacity, while the IsoSpark Duo has a flexible 8-chip capacity allowing two chip families to be run simultaneously. Both systems are fully compatible with the entire suite of IsoPlexis applications, offering the same fully automated advanced fluidics and precision imaging provided by the high-throughput IsoLight.
2020
IsoPlexis, the leader in single-cell proteomics, today announced their Single-Cell Proteomics COVID-19 Grant Challenge, where researchers are invited to share next generation insights using single-cell functional proteomics for the opportunity to win 12 IsoCode or CodePlex chips for a project run on the IsoLight system. Through this grant challenge, researchers can utilize IsoPlexis' unique single-cell proteomics to help resolve the underlying functional mechanisms of COVID-19 to help accelerate the development of novel therapies and vaccines.
Applicants should submit an abstract up to 500 words, between August 25, 2020 and September 30, 2020, proposing a project using the IsoLight platform and the Single-Cell Secretome or CodePlex Secretome solutions. A challenge committee will review the proposals and select winners based on research novelty and innovation. Experiments must be completed by November 30, 2020.
2020
IsoPlexis partners with Medquest to expand its single-cell proteomic analysis platform, the IsoLight system and IsoCode & CodePlex Chips, throughout the pharmaceutical and life science markets in Malaysia and Singapore.
IsoPlexis' unique single-cell proteomics is helping to speed development of vaccine and antiviral therapies for infectious diseases, including COVID-19. IsoPlexis is currently part of one of the largest COVID-19 consortiums in the US, with patient sample access in Seattle, Washington. Additionally, IsoPlexis has published high impact publications in research areas from cancer immunology, cellular and regenerative medicine, to infectious diseases, oncology, and neuroinflammation.
"We are privileged to partner with IsoPlexis in delivering powerful tools in the fight against cancer and advancing future medicine," said Mr. Wan Suhaimi, Managing Director of Medquest.
2020
IsoPlexis, the leader in single-cell functional proteomics products, today announced a collaboration with Lonza, a leading cell & gene therapy manufacturer, to use IsoPlexis' IsoLight platform. This automated functional proteomics analysis platform will provide quality analytics for cell therapy products generated on Lonza's Cocoon® Platform, an automated, highly flexible cell therapy manufacturing Platform.
Lonza's Cocoon® Platform allows for efficient centralized and decentralized manufacturing of novel cell therapies, and IsoPlexis' IsoLight Platform provides a solution for the functional characterization of the cell therapy product, to ensure correlative functional potency of the manufactured cell product. By using the Cocoon® Platform's automated programming and on-board, real-time analytics, the collaboration will seek to significantly improve the biological understanding of starting material, process, and product analytics to enable more efficient manufacturing and higher quality cell therapies.
2020
IsoPlexis, the leader in single-cell functional proteomics, today announced a partnership with the Division of Infectious Diseases, Department of Medicine at Columbia University, IsoPlexis' Single-Cell Secretome immune profiling solutions will be used to study cellular drivers of durable and protective immune response to COVID-19. T cell and other immune cell polyfunctional cytokine responses on IsoPlexis' platform have previously shown to be predictive of a variety of responses in human and mice studies throughout cancer immunology and infectious disease. "We are looking forward to our partnership with Columbia University in the fight against COVID-19," said IsoPlexis Chief Executive Officer, Sean Mackay. "This work will provide critical functional insights into the mechanisms of protective and durable immune response to COVID-19, especially with regards to the activity of T cells."
2020
IsoPlexis, the leader in single-cell proteomics products, today announced an exclusive agreement with Neoline Technology Co, a leading distributor for next generation analytical systems, to distribute IsoPlexis' products in China. IsoPlexis' unique single-cell proteomics is helping to speed development of vaccine and antiviral therapies for infectious disease, like COVID-19. IsoPlexis is currently part of one of the largest COVID-19 consortiums in the US, with patient sample access in Seattle, Washington. Additionally, IsoPlexis has published high impact publications in research areas from cancer immunology, cellular and regenerative medicine, to infectious diseases, oncology, and neuroinflammation.
2020
IsoPlexis, the leader in single-cell proteomics, today announced that Peter Siesel has joined the company as Chief Commercial Officer. In this role, Mr. Siesel will continue to advance IsoPlexis' commercialization and market expansion efforts by leading global sales and customer support, as well as expansion into key regions for market growth.
"We are pleased to have Peter join our executive team at IsoPlexis," said Sean Mackay, co-founder and Chief Executive Officer of IsoPlexis. "Peter has proven leadership and played a critical role in developing and expanding commercial teams in the fast-paced world of the life sciences industry. We are confident that he will bring extensive knowledge to the table and drive further global success in our rapidly growing commercial endeavors."
2020
The funds from this Phase 2 SBIR grant will be used by IsoPlexis to expand the development of a functional proteomic platform to determine effects of the inflammatory immune response on Alzheimer's progression. The IsoPlexis system will allow for the sensitive detection of responses from various immune cells such as peripheral monocytes, highly polyfunctional secretomic T cell types, and microglia, as biomarkers for early stage diagnosis and monitoring of inflammatory neurodegenerative diseases. This unique approach is non-invasive and should have broad impact and unique value for pre-clinical and clinical use.
2020
IsoPlexis, the leader in functional cellular proteomics, today announced the appointment of John Strahley as Chief Financial Officer. As CFO, Mr. Strahley will be responsible for the company's strategic planning, finance, accounting, investor relations, and treasury functions, among other pivotal roles.
"We look forward to welcoming John to IsoPlexis' executive leadership team," said Sean Mackay, co-founder and Chief Executive Officer of IsoPlexis. "John's deep experience in leading financial institutions as well as his experience with groundbreaking fast paced companies, provides the needed tools to help accelerate our mission."
2020
IsoPlexis, the leader in functional cellular proteomics, and the Institute for Systems Biology (ISB) announced a partnership mapping functional immune responses at the single cell level to study COVID-19. Uncovering functional immune responses using IsoPlexis technologies have underpinned key breakthroughs in therapies that harness the immune system across disease areas. The data from this partnership will be released as soon as possible and made globally available to researchers combatting the disease. Research will be performed on immune cells from individuals who have been diagnosed with or recovered from COVID-19. IsoPlexis' single cell functional proteomics platform will be utilized on a variety of immune cell types, including various T cells and myeloid cells to put together a map of the overall response.
2020
IsoPlexis, the leader in functional cellular proteomics, today announced the upcoming launch of two new additions to its application family, with the fully automated CodePlex Secretome solution for a faster hands-off approach to obtaining highly multiplexed bulk cytokine data and the Single-Cell Innate & Myeloid solution, which uniquely reveals functional sources of immune suppression from rare subsets of innate and myeloid cells. These new chip applications run on the revolutionary IsoLight system, which serves as a comprehensive automated proteomics hub. The CodePlex Secretome and Single-Cell Innate & Myeloid solution are now available for purchase.
2020
IsoPlexis, the leader in single-cell functional proteomics, has announced today that it has raised an additional $20 million in its Series C financing, bringing the entire Series C round to $45 million. The funding will continue to drive the global commercial expansion of its IsoLight single-cell proteomic analysis platform. The recent financing was led by Northpond Ventures, along with participation from existing investors. In 2020, IsoPlexis will continue to expand its applications and release innovation products addressing high need research areas for its existing and future customer base, including products that address innate & myeloid function, tumor cell signaling, and other high need areas.
2019
2019
IsoPlexis, the leading single-cell functional proteomics company, has announced their "Cracking the IsoCode: Single Cell Functional Biomarkers Challenge", where researchers are invited to share next generation insights using single-cell functional proteomics for the opportunity to win a project on the IsoLight system at their institution. IsoPlexis is awarding 12 IsoCode chips to two winners whose proposed projects express research novelty and innovation using single-cell functional proteomics.
2019
IsoPlexis continues to build its pipeline of revolutionary, single-cell, proteomic biology solutions with novel, tumor cell, proteomic signaling pathway technology. IsoPlexis announced today that it has received $2 million in grant funding from the National Cancer Institute's Small Business Innovation Research (NCI SBIR) Development Center for the advancement of intracellular proteomic pathway targeting solutions for single tumor cell analyses.
2019
IsoPlexis, the leader in single-cell functional proteomics, today launched its IsoSpeak Software for automated on-site analysis and advanced, functional, single cell mapping, and two new additions to its application family, with its murine cell solution for pre-clinical immunotherapy profiling and its polyfunctional inflammation solution for profiling a range of inflammatory diseases.
2019
IsoPlexis, the leader in single-cell functional proteomics, continues to accelerate immunotherapy development with its IsoLight system, which was highlighted in the recent publication, Biomarkers for Immunotherapy of Cancer. The Springer Protocols book outlines emerging standards for cancer immunotherapy biomarker analysis.
2019
IsoPlexis, the leader in single-cell functional proteomics, continues to build upon recent success in the CAR-T field through NCI funding, advanced cell therapy data sets, and with the release of a co-marketing Tech Note with Miltenyi Biotec, Inc. IsoPlexis & Miltenyi Biotec, Inc. published a technology note showcasing how their respective technologies can be used synergistically to optimize CAR-T bioprocessing workflows. In particular, IsoPlexis' single-cell functional characterization was used to evaluate cell therapy process changes, downstream of Miltenyi Biotec, Inc.'s CliniMACS Prodigy® system.
2019
IsoPlexis, the leader in single-cell functional proteomics products, today announced an exclusive agreement with BioStream Co, a leading distributor for next generation analytical systems, to distribute IsoPlexis' products in Japan. "We are very excited to partner with BioStream, a world class distributor of life science systems and technology in Japan," said IsoPlexis Chief Executive Officer, Sean Mackay. "Our single-cell proteomics platform provides a wide range of applications across development and biomarker discovery in cancer immunotherapy, and we look forward to our systems generating impactful data at leading Japanese pharmaceutical companies, research laboratories, and academic institutions."
2019
IsoPlexis, the leading life sciences company in the single-cell functional biology space, has installed its innovative IsoLight single cell cytokine detection system at the Karolinska Institute in Sweden, as part of its expansion into Europe. In addition, IsoPlexis launched its first European office in the UK. This launch marks a significant milestone for IsoPlexis as they seek to advance both single-cell biology and precision medicine in Europe. Dr. Petter Brodin, Associate Professor of Immunology at the Karolinska Institute and Director of SciLifeLab Mass Cytometry Facility in Stockholm, stated, "We are excited to use the IsoLight to perform detailed functional analyses of immune cells sampled from newborn children during their first months and years of life. The ability of the IsoLight to provide detailed analyses from very few cells is key, given that we are limited to small sample quantities of blood."
2019
IsoPlexis, a company focused on advancing single-cell functional biomarkers to address critical challenges in oncology & beyond, today announced that it has received $4 million in grant funding from the National Cancer Institute's Small Business Innovation Research (NCI SBIR) Development Center as a part of the commercialization of the IsoLight system for use in CAR-T therapy product evaluation, quality check pre-infusion, and correlative studies. "This new funding demonstrates our leadership in and commitment to advancing the future of next generation CAR-T and other engineered T-cell therapies in blood cancers, solid tumor, and beyond" said Sean Mackay, IsoPlexis Chief Executive Officer and Co-Founder. "We appreciate the continued support of the National Cancer Institute and are excited to be in a position to accelerate the progress in this already fast-moving field."
2019
IsoPlexis announced today that it had raised $25 million in Series C funding. The round was led by Northpond Ventures and included new strategic investment along with current investors Spring Mountain Capital, Ironwood Capital, North Sound Capital, and Connecticut Innovations. "We are pleased to lead the financing of IsoPlexis, an emerging leader in single cell analysis, which is catalyzing research in immunotherapy as well as a number of other high value applications," said Chris MacGriff of Northpond Ventures. In continuing its path forward, IsoPlexis continues to utilize its internal application engine and its partnerships with university professors and co-founders to build innovative single-cell products addressing high need disease areas. Additionally, IsoPlexis will expand its global operational, manufacturing, and commercial team across US, Europe and Asia, to add to the 105 employees IsoPlexis has currently.
2018
2018
The IsoLight sample-to-answer instrument receives the Red Dot Design Award for high design quality and focus on the user experience within the life sciences instrumentation category. The IsoLight's integrated design combines precision imaging and fluidics with a user-friendly software interface to create a uniquely easy to use single-cell system.
2018
The clinical data demonstrates a significant association between the functionality of anti-CD19 CAR-T cell product before treatment, as defined by IsoPlexis' Polyfunctional Strength Index (PSI), and the objective response in patients with non-Hodgkin lymphoma. The results highlight the potential to predict whether cancer patients will respond to CAR-T cell therapy before treatment, as well as to improve both pre-infusion product potency testing and guide cell product optimization. These findings have been published in Blood and are the result of a collaboration between IsoPlexis and Kite, a Gilead Company. Researchers used the IsoCode, IsoPlexis' single-cell precision engineering platform, to analyze CAR-T cell therapy products from 20 patients with non-Hodgkin lymphoma. Using IsoCode, researchers captured data to determine the PSI of each product. This PSI metric was associated with complete or partial patient response to the anti-CD19 CAR-T cell product. Other pre-infusion metrics tested in this study were not predictive.
2018
The collaboration is focused on further defining the functional impact of NKTR-214 in the clinic, at the single-cell level, with the goal of revealing both mechanism and potential immune correlates with outcome. Recently, preclinical data captured by IsoPlexis' IsoCode Chip in a study led by UCLA (AACR 2018) provided evidence that Nektar's cytokine agonist NKTR-214 can significantly boost the activation of critical T cell subsets, termed polyfunctional T cells, in combination with adoptive cell transfer (ACT) therapies.
2018
The sample-to-answer IsoLight benchtop system analyzes IsoPlexis' IsoCode chip to provide clinical and translational researchers a powerful, yet straightforward solution for establishing immune response functional correlates with outcome in key therapeutic areas like CAR-T and other cellular immunotherapies. The IsoCode Chip was recognized as The Scientist's and Fierce Life Science's #1 innovation of 2017 for its ability to provide both single-cell sensitivity and highly multiplexed and quantitative functional ELISA detection together for the first time.
2018
IsoPlexis announced today an exclusive agreement with Tekon Biotech, a leading instrumentation distributor, to distribute IsoPlexis' products in China. Tekon Biotech's first conference featuring IsoPlexis's systems will be held at Purple Mountain Hotel, Pudong, on September 20th, 2018 in Shanghai. "We are very excited to partner with Tekon Biotech, a world class distributor of life science systems and technology in China," said IsoPlexis Chief Executive Officer, Sean Mackay. "We see significant demand for our unique single-cell platform from leading Chinese pharmaceutical companies, research laboratories, and academic institutions. We are confident this partnership will help accelerate research in the fast emerging CAR-T therapy area in China, as we continue to extend our single-cell leadership into new markets."
2018
IsoPlexis, the leading developer of single-cell analytics solutions which enables complete immune cell profiling, has placed its ground-breaking IsoLight platform at City of Hope, a world-renowned independent research and treatment center for cancer, diabetes and other life-threatening diseases. IsoPlexis provides early access to its innovative platform to leading biopharmaceutical companies, researchers, and trial centers to generate proof of concept data and to solve immediate challenges in the fast moving immune-oncology field and beyond.
2017
2017
Research using novel single-cell detection technology being commercialized by IsoPlexis, called the Iso-Omix Chip, was highlighted in the Proceedings of the National Academy of Sciences. "Our single-cell proteomics technology allowed us to profile signaling pathways in melanoma cells that were both suppressed and activated via drugging. This, in turn, revealed how the cancer cells adapted and developed resistance to targeted treatments," said Dr. James Heath, a co-author of the UCLA paper and the Elizabeth W. Gilloon Professor of Chemistry at Caltech.
2017
“We’re excited to use this NIH grant support to advance our research and development in areas of solid tumor immunotherapies, bone marrow disease, autoimmune diseases and infectious diseases,” said Sean Mackay, IsoPlexis CEO and Co-Founder. “By expanding the application of our single-cell detection technologies, we aim to enable clinical researchers to better target their personalized treatments, at the single-cell level, and improve outcomes for high-need patients.”
2017
"This new grant demonstrates the commitment to advancing CAR-T through investments, not only in the area of therapeutic discovery, but also in next-generation engineering technology," said Sean Mackay, IsoPlexis Chief Executive Officer and Co-Founder. "We're excited to be in a position to further enable this fast-growing field to better characterize and understand these complex therapies, and improve treatments for high-need patients."
2017
The Series B financing round was led by Spring Mountain Capital, with participation by Connecticut Innovations, North Sound Ventures, and Ironwood Capital. "IsoPlexis' collaboration data and product development has continued to demonstrate both the need for the IsoPlexis technology and the potential to have a large impact on improving patient outcomes," said Gregory P. Ho, President of Spring Mountain Capital and IsoPlexis Board Director. "We are excited to continue our partnership with the IsoPlexis team to move the company forward."
2017
IsoPlexis collaboration offers breakthrough insights into detecting and predicting patient response to t-cell therapy. Data captured by IsoCode, IsoPlexis' single-cell precision engineering platform, detected a statistically significant association between the potency of CAR-T cell product prior to treatment and objective response of cancer patients post-treatment. The results highlight the potential to predict whether cancer patients will respond to CAR-T cell therapy prior to treatment, as well as to improve both pre-infusion potency testing and cell product design.
2017
IsoPlexis was recently awarded a competitive Phase I Small Business Innovation Research (SBIR) grant from the National Cancer Institute of the National Institutes of Health to develop a multi-protein, single-cell analysis platform to facilitate personalized cancer immunotherapy response detection.
2017
IsoPlexis was recently awarded a competitive Phase I Small Business Innovation Research (SBIR) grant from the National Institute on Aging of the National Institutes of Health to develop a system to analyze trafficking leukocytes' highly multiplexed proteomic responses in patients with Alzheimer's disease.
2017
IsoCode, IsoPlexis' single-cell precision platform, captured novel data from CAR-T products developed by Novartis Pharmaceuticals (Novartis), leading to IsoPlexis' development of new bioinformatics tools for visualizing high-dimensional, single-cell, proteomics data. Researchers from IsoPlexis and Novartis published the results from their collaboration in the November issue of the Journal for ImmunoTherapy of Cancer.
2017
IsoPlexis’ single-cell technology recognized as a detection system poised to revolutionize clinical research and advance scientific knowledge. "Being named The Scientist’s No. 1 innovation of 2017 is another validation of the IsoPlexis technology’s role in utilizing our immune system to fight cancer," said Rong Fan, Ph.D., IsoPlexis Co-Founder and Scientific Advisory Board Chair, and an Associate Professor of Biomedical Engineering at Yale University. "IsoPlexis’ technology is helping researchers capture and understand large quantities of highly precise data, which will lead to more potent immunotherapies for more patients."
2017
IsoPlexis’ IsoCode Chip and IsoLight Platform recognized by publishers of FierceBiotech and FiercePharma as this year’s top technology innovation in the life sciences space. "It is an honor to receive this award from the publishers of FierceBiotech and FiercePharma," said Sean Mackay, IsoPlexis Chief Executive Officer and Co-Founder. "Clinical researchers at leading academic and biopharmaceutical labs are using IsoPlexis technology to better understand how to use the human immune system in the fight against cancer, and we're proud that our technology is helping to advance more personalized and more potent immunotherapies for patients that need them the most."
2015
Spark the Next Breakthrough